1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsTranslational Partnerships Awards Program RFA is sponsored by UNMC / Fred & Pamela Buffett Cancer Center. This internal UNMC program focuses on translational partnerships. Research on NCDs in LMICs often requires translational approaches, making this a potential fit for university researchers if the partnership is with an LMIC institution.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Internal Awards and Pilot Grants | Fred & Pamela Buffett Cancer Center | University of Nebraska Medical Center Internal Awards and Pilot Grants Funding ranges from $25,000 to $150,000, depending on the funding program. Please refer to the individual Request for Applications (RFAs) for details.
American Cancer Society Institutional Research Grant Pilot Award The American Cancer Society Institutional Research Grant (ACS IRG) Pilot Award administered by the Cancer Center supports early-stage investigators. Funding period: 1-year project period Funding cycle: Application is expected to open in October, subject to changes in the funding schedule.
Community Outreach and Engagement Pilot Project Program The Community Outreach and Engagement (COE) Pilot Project Program supports research informed or advised by community members in the Catchment Area (Nebraska). Projects must address the Catchment Area priority cancers [brain, breast, GI (colorectal, pancreatic), lung, and prostate], and have potential to lead to peer-reviewed external funding.
Funding period: 1-year project period Funding cycle: Application is expected to open in March, subject to changes in the funding schedule.
Cancer Prevention and Control Program Pilot Grant The Cancer Prevention and Control Program (CPCP) Pilot Grant supports innovative cancer prevention and control projects aligned with the program's three aims: Understanding cancer risk factors Developing novel screening/prevention methods Improving survivor outcomes.
With a special emphasis on community-engaged research, priority cancers [brain, breast, GI (colorectal, pancreatic), lung, and prostate], and the Cancer Center’s strategic themes. Funding period: 1-year project period Funding cycle: Application is expected to open in May, subject to changes in the funding schedule.
High-Risk, High-Reward Pilot Projects Program Funding period: 1-year project period Funding cycle: Application is expected to open in May, subject to changes in the funding schedule. Investigator-Initiated Clinical Trial (IIT) Team Award The Investigator-Initiated Clinical Trial (IIT) Team Award supports the development of investigator-initiated trials. Proposals must include a timeline to open an IIT within two years of award.
Funding period: 1-2 years project period Funding cycle: Application is expected to open in May, subject to changes in the funding schedule. The R01 Investment Program supports members who have applied for a cancer-focused NIH R01, received an encouraging score that is below the funding threshold, and are working toward resubmission. The program provides funding to help generate additional data needed for successful resubmission.
Funding period: 1-year project period Funding cycle: Applications are accepted on a rolling basis. Translational Partnerships Awards Program The Translational Partnerships Awards Program supports collaborative translational cancer research that advances the development of innovative cancer therapies and generates preliminary preclinical data.
The program fosters partnerships between basic and clinical cancer researchers, with priority given to projects addressing Catchment Area priority cancers [brain, breast, GI (colorectal, pancreatic), lung, and prostate], and advancing investigator-initiated clinical interventional treatment trials. Funding period: 1-year project period Funding cycle: Applications are accepted on a rolling basis.
Team Science Awards Program The Team Science Awards Program supports collaborative, cross-disciplinary cancer research projects that catalyze the development of multi-component grant applications, including program project (NIH P awards) and cooperative agreement (NIH U awards) funding mechanisms. The program is designed to strengthen research collaborations and position investigators for successful external funding.
Funding period: 1-year project period Funding cycle: Announced periodically Transdisciplinary Research Award Program The Transdisciplinary Research Award Program is the expansion of transdisciplinary research in the three thematic areas strategically determined by the Cancer Center based upon research strengths and the needs of the Catchment Area (Nebraska).
Cancer and Environmental Circumstances Novel Cancer Therapeutic Interventions This pilot award program is envisioned as a catalyst to increase the depth and breadth of transdisciplinary research at the Fred & Pamela Buffett Cancer Center. Funding period: 1-year project period Funding cycle: Application is expected to open in February, subject to changes in the funding schedule.
Cancer Prevention and Control Seed Grant The Cancer Prevention and Control (CPCP) Seed Grant is designed to spark innovative research aligning with CPCP’s scientific goals and to foster productive and sustainable collaborations across CPCP and throughout the Cancer Center community. Project period: 1-year project period Funding cycle: Application is expected to open in October, subject to changes in the funding schedule.
Cancer Biology Program Seed Grant The Cancer Biology Program (CBP) Seed Grant supports sustainable intra-programmatic collaborations aligned with CBP’s scientific goals. The seed grant is open to current CBP full members. The number of awards and funding support may vary by funding cycle.
Funding period: 1-year project period Funding cycle: Application is expected to open in January, subject to changes in the funding schedule. Translational Cancer Research Program Seed Grant The Translational Cancer Research Program (TCRP) Seed Grant is designed to foster sustainable intra-programmatic collaborations across the Translational Cancer Research Program (TCRP).
All proposals must directly align with at least one TCRP specific aim and at least one Cancer Center’s transdisciplinary theme. Contact PI must be a current TCRP full member. Funding period: 1-year project period Funding cycle: Application is expected to open in March, subject to changes in the funding schedule.
According to the current listing, eligibility includes: Eligible researchers at UNMC / Fred & Pamela Buffett Cancer Center. Confirm the full requirements in the official notice before applying.
Translational Partnerships Awards Program RFA is funded by UNMC / Fred & Pamela Buffett Cancer Center. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
On July 14, 2026, Warren Buffett routed his roughly $6 billion annual Berkshire gift to four family foundations and excluded the Gates Foundation — the first exclusion since 2006, pending a review of the foundation's historical ties to Jeffrey Epstein. Buffett has given the Gates Foundation more than $43 billion over two decades. Here is why the pause matters for the world's largest grantmaker, what it reveals about concentration risk in modern philanthropy, and what nonprofits that depend on a single major funder should do now.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read article